The global Virus like Particle (VLP) Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo. While they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another essential advantage of VLPs is that they more effectively activate critical aspects of the immune response to achieve potent immune stimulation and provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are currently used for several diseases.

North American market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Virus like Particle (VLP) Vaccines include AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Virus like Particle (VLP) Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus like Particle (VLP) Vaccines.

The Virus like Particle (VLP) Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Virus like Particle (VLP) Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Virus like Particle (VLP) Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Virus like Particle (VLP) Vaccines Market Report

Report Metric	Details
Report Name	Virus like Particle (VLP) Vaccines Market
Segment by Type	Prophylactic Vaccine Therapeutic Vaccine
Segment by Application	Hepatitis B Virus (HBV) Human Papillomavirus (HPV) Hepatitis E Virus (HEV) Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Virus like Particle (VLP) Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Virus like Particle (VLP) Vaccines Market report?

Ans: The main players in the Virus like Particle (VLP) Vaccines Market are AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd.

What are the Application segmentation covered in the Virus like Particle (VLP) Vaccines Market report?

Ans: The Applications covered in the Virus like Particle (VLP) Vaccines Market report are Hepatitis B Virus (HBV), Human Papillomavirus (HPV), Hepatitis E Virus (HEV), Other

What are the Type segmentation covered in the Virus like Particle (VLP) Vaccines Market report?

Ans: The Types covered in the Virus like Particle (VLP) Vaccines Market report are Prophylactic Vaccine, Therapeutic Vaccine

1 Virus like Particle (VLP) Vaccines Market Overview

1.1 Product Definition

1.2 Virus like Particle (VLP) Vaccines by Type

1.2.1 Global Virus like Particle (VLP) Vaccines Market Value Comparison by Type (2024-2030)

1.2.2 Prophylactic Vaccine

1.2.3 Therapeutic Vaccine

1.3 Virus like Particle (VLP) Vaccines by Application

1.3.1 Global Virus like Particle (VLP) Vaccines Market Value by Application (2024-2030)

1.3.2 Hepatitis B Virus (HBV)

1.3.3 Human Papillomavirus (HPV)

1.3.4 Hepatitis E Virus (HEV)

1.3.5 Other

1.4 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts

1.4.1 Global Virus like Particle (VLP) Vaccines Revenue 2019-2030

1.4.2 Global Virus like Particle (VLP) Vaccines Sales 2019-2030

1.4.3 Global Virus like Particle (VLP) Vaccines Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Virus like Particle (VLP) Vaccines Market Competition by Manufacturers

2.1 Global Virus like Particle (VLP) Vaccines Sales Market Share by Manufacturers (2019-2024)

2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Virus like Particle (VLP) Vaccines Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Virus like Particle (VLP) Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Product Type & Application

2.7 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Date of Enter into This Industry

2.8 Global Virus like Particle (VLP) Vaccines Market Competitive Situation and Trends

2.8.1 Global Virus like Particle (VLP) Vaccines Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Virus like Particle (VLP) Vaccines Players Market Share by Revenue

2.8.3 Global Virus like Particle (VLP) Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Virus like Particle (VLP) Vaccines Market Scenario by Region

3.1 Global Virus like Particle (VLP) Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2019-2030

3.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2019-2024

3.2.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2025-2030

3.3 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2019-2030

3.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2019-2024

3.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2025-2030

3.4 North America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country

3.4.1 North America Virus like Particle (VLP) Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2019-2030)

3.4.3 North America Virus like Particle (VLP) Vaccines Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Virus like Particle (VLP) Vaccines Market Facts & Figures by Country

3.5.1 Europe Virus like Particle (VLP) Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2019-2030)

3.5.3 Europe Virus like Particle (VLP) Vaccines Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Virus like Particle (VLP) Vaccines Market Facts & Figures by Region

3.6.1 Asia Pacific Virus like Particle (VLP) Vaccines Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (2019-2030)

3.6.3 Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country

3.7.1 Latin America Virus like Particle (VLP) Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Virus like Particle (VLP) Vaccines Sales by Country (2019-2030)

3.7.3 Latin America Virus like Particle (VLP) Vaccines Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Virus like Particle (VLP) Vaccines Market Facts & Figures by Country

3.8.1 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2019-2030)

3.8.3 Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2019-2030)

4.1.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2019-2024)

4.1.2 Global Virus like Particle (VLP) Vaccines Sales by Type (2025-2030)

4.1.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2019-2030)

4.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2019-2030)

4.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Type (2019-2024)

4.2.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2025-2030)

4.2.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2019-2030)

4.3 Global Virus like Particle (VLP) Vaccines Price by Type (2019-2030)

5 Segment by Application

5.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2019-2030)

5.1.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2019-2024)

5.1.2 Global Virus like Particle (VLP) Vaccines Sales by Application (2025-2030)

5.1.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2019-2030)

5.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2019-2030)

5.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Application (2019-2024)

5.2.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2025-2030)

5.2.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2019-2030)

5.3 Global Virus like Particle (VLP) Vaccines Price by Application (2019-2030)

6 Key Companies Profiled

6.1 AstraZeneca Group (Icosavax)

6.1.1 AstraZeneca Group (Icosavax) Company Information

6.1.2 AstraZeneca Group (Icosavax) Description and Business Overview

6.1.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.1.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio

6.1.5 AstraZeneca Group (Icosavax) Recent Developments/Updates

6.2 Premas Biotech

6.2.1 Premas Biotech Company Information

6.2.2 Premas Biotech Description and Business Overview

6.2.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio

6.2.5 Premas Biotech Recent Developments/Updates

6.3 BioAgilytix

6.3.1 BioAgilytix Company Information

6.3.2 BioAgilytix Description and Business Overview

6.3.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.3.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio

6.3.5 BioAgilytix Recent Developments/Updates

6.4 Coriolis

6.4.1 Coriolis Company Information

6.4.2 Coriolis Description and Business Overview

6.4.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio

6.4.5 Coriolis Recent Developments/Updates

6.5 Charles River Laboratories

6.5.1 Charles River Laboratories Company Information

6.5.2 Charles River Laboratories Description and Business Overview

6.5.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio

6.5.5 Charles River Laboratories Recent Developments/Updates

6.6 VBI Vaccines Inc

6.6.1 VBI Vaccines Inc Company Information

6.6.2 VBI Vaccines Inc Description and Business Overview

6.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio

6.6.5 VBI Vaccines Inc Recent Developments/Updates

6.7 Creative Biostructure

6.7.1 Creative Biostructure Company Information

6.7.2 Creative Biostructure Description and Business Overview

6.7.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio

6.7.5 Creative Biostructure Recent Developments/Updates

6.8 WuXi Biologics

6.8.1 WuXi Biologics Company Information

6.8.2 WuXi Biologics Description and Business Overview

6.8.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.8.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio

6.8.5 WuXi Biologics Recent Developments/Updates

6.9 Creative Diagnostics

6.9.1 Creative Diagnostics Company Information

6.9.2 Creative Diagnostics Description and Business Overview

6.9.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio

6.9.5 Creative Diagnostics Recent Developments/Updates

6.10 Shanghai Bovax Biotechnology Co., Ltd.

6.10.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information

6.10.2 Shanghai Bovax Biotechnology Co., Ltd. Description and Business Overview

6.10.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio

6.10.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments/Updates

6.11 Junshi Biosciences

6.11.1 Junshi Biosciences Company Information

6.11.2 Junshi Biosciences Description and Business Overview

6.11.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio

6.11.5 Junshi Biosciences Recent Developments/Updates

6.12 Luye Pharma Group

6.12.1 Luye Pharma Group Company Information

6.12.2 Luye Pharma Group Description and Business Overview

6.12.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio

6.12.5 Luye Pharma Group Recent Developments/Updates

6.13 Chengdu Kanghua Biological Products Co., Ltd.

6.13.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information

6.13.2 Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview

6.13.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio

6.13.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Virus like Particle (VLP) Vaccines Industry Chain Analysis

7.2 Virus like Particle (VLP) Vaccines Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Virus like Particle (VLP) Vaccines Production Mode & Process

7.4 Virus like Particle (VLP) Vaccines Sales and Marketing

7.4.1 Virus like Particle (VLP) Vaccines Sales Channels

7.4.2 Virus like Particle (VLP) Vaccines Distributors

7.5 Virus like Particle (VLP) Vaccines Customers

8 Virus like Particle (VLP) Vaccines Market Dynamics

8.1 Virus like Particle (VLP) Vaccines Industry Trends

8.2 Virus like Particle (VLP) Vaccines Market Drivers

8.3 Virus like Particle (VLP) Vaccines Market Challenges

8.4 Virus like Particle (VLP) Vaccines Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Premas Biotech

BioAgilytix

Coriolis

Charles River Laboratories

VBI Vaccines Inc

Creative Biostructure

Wuxi Biologics

Creative Diagnostics

Shanghai Bovax Biotechnology Co., Ltd.

Junshi Biosciences

Luye Pharma Group

Chengdu Kanghua Biological Products Co.,Ltd.

AstraZeneca Group (Icosavax)

List of Tables

Table 1. Global Virus like Particle (VLP) Vaccines Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Virus like Particle (VLP) Vaccines Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Virus like Particle (VLP) Vaccines Market Competitive Situation by Manufacturers in 2023

Table 4. Global Virus like Particle (VLP) Vaccines Sales (K Dose) of Key Manufacturers (2019-2024)

Table 5. Global Virus like Particle (VLP) Vaccines Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Virus like Particle (VLP) Vaccines Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Virus like Particle (VLP) Vaccines Average Price (US$/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Virus like Particle (VLP) Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Product Type & Application

Table 12. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Virus like Particle (VLP) Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Virus like Particle (VLP) Vaccines as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Virus like Particle (VLP) Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Virus like Particle (VLP) Vaccines Sales by Region (2019-2024) & (K Dose)

Table 18. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2019-2024)

Table 19. Global Virus like Particle (VLP) Vaccines Sales by Region (2025-2030) & (K Dose)

Table 20. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2025-2030)

Table 21. Global Virus like Particle (VLP) Vaccines Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2019-2024)

Table 23. Global Virus like Particle (VLP) Vaccines Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2025-2030)

Table 25. North America Virus like Particle (VLP) Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Virus like Particle (VLP) Vaccines Sales by Country (2019-2024) & (K Dose)

Table 27. North America Virus like Particle (VLP) Vaccines Sales by Country (2025-2030) & (K Dose)

Table 28. North America Virus like Particle (VLP) Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Virus like Particle (VLP) Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Virus like Particle (VLP) Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Virus like Particle (VLP) Vaccines Sales by Country (2019-2024) & (K Dose)

Table 32. Europe Virus like Particle (VLP) Vaccines Sales by Country (2025-2030) & (K Dose)

Table 33. Europe Virus like Particle (VLP) Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Virus like Particle (VLP) Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (2019-2024) & (K Dose)

Table 37. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (2025-2030) & (K Dose)

Table 38. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Virus like Particle (VLP) Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Virus like Particle (VLP) Vaccines Sales by Country (2019-2024) & (K Dose)

Table 42. Latin America Virus like Particle (VLP) Vaccines Sales by Country (2025-2030) & (K Dose)

Table 43. Latin America Virus like Particle (VLP) Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2019-2024) & (K Dose)

Table 47. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2025-2030) & (K Dose)

Table 48. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Type (2019-2024)

Table 51. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Type (2025-2030)

Table 52. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2019-2024)

Table 53. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2025-2030)

Table 54. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2019-2024)

Table 57. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2025-2030)

Table 58. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2019-2024)

Table 59. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2025-2030)

Table 60. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Application (2019-2024)

Table 61. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Application (2025-2030)

Table 62. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2019-2024)

Table 63. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2025-2030)

Table 64. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2019-2024)

Table 67. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2025-2030)

Table 68. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2019-2024)

Table 69. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2025-2030)

Table 70. AstraZeneca Group (Icosavax) Company Information

Table 71. AstraZeneca Group (Icosavax) Description and Business Overview

Table 72. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 73. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product

Table 74. AstraZeneca Group (Icosavax) Recent Developments/Updates

Table 75. Premas Biotech Company Information

Table 76. Premas Biotech Description and Business Overview

Table 77. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 78. Premas Biotech Virus like Particle (VLP) Vaccines Product

Table 79. Premas Biotech Recent Developments/Updates

Table 80. BioAgilytix Company Information

Table 81. BioAgilytix Description and Business Overview

Table 82. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 83. BioAgilytix Virus like Particle (VLP) Vaccines Product

Table 84. BioAgilytix Recent Developments/Updates

Table 85. Coriolis Company Information

Table 86. Coriolis Description and Business Overview

Table 87. Coriolis Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 88. Coriolis Virus like Particle (VLP) Vaccines Product

Table 89. Coriolis Recent Developments/Updates

Table 90. Charles River Laboratories Company Information

Table 91. Charles River Laboratories Description and Business Overview

Table 92. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 93. Charles River Laboratories Virus like Particle (VLP) Vaccines Product

Table 94. Charles River Laboratories Recent Developments/Updates

Table 95. VBI Vaccines Inc Company Information

Table 96. VBI Vaccines Inc Description and Business Overview

Table 97. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 98. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product

Table 99. VBI Vaccines Inc Recent Developments/Updates

Table 100. Creative Biostructure Company Information

Table 101. Creative Biostructure Description and Business Overview

Table 102. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 103. Creative Biostructure Virus like Particle (VLP) Vaccines Product

Table 104. Creative Biostructure Recent Developments/Updates

Table 105. WuXi Biologics Company Information

Table 106. WuXi Biologics Description and Business Overview

Table 107. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 108. WuXi Biologics Virus like Particle (VLP) Vaccines Product

Table 109. WuXi Biologics Recent Developments/Updates

Table 110. Creative Diagnostics Company Information

Table 111. Creative Diagnostics Description and Business Overview

Table 112. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 113. Creative Diagnostics Virus like Particle (VLP) Vaccines Product

Table 114. Creative Diagnostics Recent Developments/Updates

Table 115. Shanghai Bovax Biotechnology Co., Ltd. Company Information

Table 116. Shanghai Bovax Biotechnology Co., Ltd. Description and Business Overview

Table 117. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 118. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product

Table 119. Shanghai Bovax Biotechnology Co., Ltd. Recent Developments/Updates

Table 120. Junshi Biosciences Company Information

Table 121. Junshi Biosciences Description and Business Overview

Table 122. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 123. Junshi Biosciences Virus like Particle (VLP) Vaccines Product

Table 124. Junshi Biosciences Recent Developments/Updates

Table 125. Luye Pharma Group Company Information

Table 126. Luye Pharma Group Description and Business Overview

Table 127. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 128. Luye Pharma Group Virus like Particle (VLP) Vaccines Product

Table 129. Luye Pharma Group Recent Developments/Updates

Table 130. Chengdu Kanghua Biological Products Co., Ltd. Company Information

Table 131. Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview

Table 132. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 133. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product

Table 134. Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Virus like Particle (VLP) Vaccines Distributors List

Table 138. Virus like Particle (VLP) Vaccines Customers List

Table 139. Virus like Particle (VLP) Vaccines Market Trends

Table 140. Virus like Particle (VLP) Vaccines Market Drivers

Table 141. Virus like Particle (VLP) Vaccines Market Challenges

Table 142. Virus like Particle (VLP) Vaccines Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Virus like Particle (VLP) Vaccines

Figure 2. Global Virus like Particle (VLP) Vaccines Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Virus like Particle (VLP) Vaccines Market Share by Type: 2023 & 2030

Figure 4. Prophylactic Vaccine Product Picture

Figure 5. Therapeutic Vaccine Product Picture

Figure 6. Global Virus like Particle (VLP) Vaccines Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global Virus like Particle (VLP) Vaccines Market Share by Application: 2023 & 2030

Figure 8. Hepatitis B Virus (HBV)

Figure 9. Human Papillomavirus (HPV)

Figure 10. Hepatitis E Virus (HEV)

Figure 11. Other

Figure 12. Global Virus like Particle (VLP) Vaccines Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Virus like Particle (VLP) Vaccines Market Size (2019-2030) & (US$ Million)

Figure 14. Global Virus like Particle (VLP) Vaccines Sales (2019-2030) & (K Dose)

Figure 15. Global Virus like Particle (VLP) Vaccines Average Price (US$/Dose) & (2019-2030)

Figure 16. Virus like Particle (VLP) Vaccines Report Years Considered

Figure 17. Virus like Particle (VLP) Vaccines Sales Share by Manufacturers in 2023

Figure 18. Global Virus like Particle (VLP) Vaccines Revenue Share by Manufacturers in 2023

Figure 19. Global 5 and 10 Largest Virus like Particle (VLP) Vaccines Players: Market Share by Revenue in Virus like Particle (VLP) Vaccines in 2023

Figure 20. Virus like Particle (VLP) Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 21. Global Virus like Particle (VLP) Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2019-2030)

Figure 23. North America Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2019-2030)

Figure 24. United States Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country (2019-2030)

Figure 27. Europe Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2019-2030)

Figure 28. Germany Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Virus like Particle (VLP) Vaccines Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2019-2030)

Figure 35. China Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2019-2030)

Figure 43. Mexico Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Colombia Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2019-2030)

Figure 48. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Virus like Particle (VLP) Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Virus like Particle (VLP) Vaccines by Type (2019-2030)

Figure 53. Global Revenue Market Share of Virus like Particle (VLP) Vaccines by Type (2019-2030)

Figure 54. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2019-2030)

Figure 55. Global Sales Market Share of Virus like Particle (VLP) Vaccines by Application (2019-2030)

Figure 56. Global Revenue Market Share of Virus like Particle (VLP) Vaccines by Application (2019-2030)

Figure 57. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2019-2030)

Figure 58. Virus like Particle (VLP) Vaccines Value Chain

Figure 59. Virus like Particle (VLP) Vaccines Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions